These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 34497008)
1. Updated Meta-Analysis of Cardiovascular Outcome Trials Evaluating Cardiovascular Efficacy of Glucagon-Like Peptide-1 Receptor Agonists. Patoulias D; Papadopoulos C; Kassimis G; Karagiannis A; Doumas M Am J Cardiol; 2021 Nov; 159():143-146. PubMed ID: 34497008 [No Abstract] [Full Text] [Related]
2. [Clinical Efficacy and Mechanisms of Actions of the Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and High Risk of Cardiovascular Diseases]. Gilarevsky SR Kardiologiia; 2021 May; 61(4):66-72. PubMed ID: 33998411 [TBL] [Abstract][Full Text] [Related]
3. Update in Cardiovascular Safety of Glucagon Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. A Mixed Treatment Comparison Meta-Analysis of Randomised Controlled Trials. Al Yami MS; Alfayez OM; Alsheikh R Heart Lung Circ; 2018 Nov; 27(11):1301-1309. PubMed ID: 29887418 [TBL] [Abstract][Full Text] [Related]
4. Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial. Athyros VG; Katsiki N; Tentolouris N Curr Vasc Pharmacol; 2016; 14(5):469-473. PubMed ID: 27633290 [No Abstract] [Full Text] [Related]
5. No pancreatic safety concern following glucagon-like peptide-1 receptor agonist therapies: A pooled analysis of cardiovascular outcome trials. Liu Y; Tian Q; Yang J; Wang H; Hong T Diabetes Metab Res Rev; 2018 Nov; 34(8):e3061. PubMed ID: 30109766 [TBL] [Abstract][Full Text] [Related]
6. Glucagon-like Peptide-1 Receptor Agonists Cardio-protective Effects: An Umbrella Review. Elnour AA; Al Hajri N; El Khidir IY; AlAmoodi A; Ahmed SA; Sadeq A Curr Diabetes Rev; 2020; 16(8):820-832. PubMed ID: 32442089 [TBL] [Abstract][Full Text] [Related]
7. Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and Cardiovascular Outcomes: A Meta-analysis. Peterson SC; Barry AR Curr Diabetes Rev; 2018; 14(3):273-279. PubMed ID: 28413990 [TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL. Torekov SS Cardiovasc Res; 2018 Aug; 114(10):e70-e71. PubMed ID: 30052921 [No Abstract] [Full Text] [Related]
9. Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta-analysis and subgroup analysis of randomized controlled trials. Mannucci E; Dicembrini I; Nreu B; Monami M Diabetes Obes Metab; 2020 Feb; 22(2):203-211. PubMed ID: 31595657 [TBL] [Abstract][Full Text] [Related]
11. Glucagon-like peptide-1 receptor agonists as anti-inflammatory agents: A potential mode of cardiovascular benefits. Salem AM; Bain SC; Obaid DR Atherosclerosis; 2022 Jul; 352():83-84. PubMed ID: 35662526 [No Abstract] [Full Text] [Related]
12. Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis. Hussein H; Zaccardi F; Khunti K; Seidu S; Davies MJ; Gray LJ Diabet Med; 2019 Apr; 36(4):444-452. PubMed ID: 30653708 [TBL] [Abstract][Full Text] [Related]
13. Inquiries Into the Mechanisms by Which GLP-1 Receptor Agonists Reduce Cardiovascular Risk in Diabetes. Inzucchi SE; Arai AE J Am Coll Cardiol; 2024 Aug; 84(6):558-560. PubMed ID: 39084830 [No Abstract] [Full Text] [Related]
14. Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - A systematic review and meta-analysis. Goldenberg RM J Diabetes Complications; 2022 Sep; 36(9):108285. PubMed ID: 35998555 [No Abstract] [Full Text] [Related]
15. Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis. Alfayez OM; Almohammed OA; Alkhezi OS; Almutairi AR; Al Yami MS Cardiovasc Diabetol; 2020 Jun; 19(1):96. PubMed ID: 32571416 [TBL] [Abstract][Full Text] [Related]
16. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials. Marsico F; Paolillo S; Gargiulo P; Bruzzese D; Dell'Aversana S; Esposito I; Renga F; Esposito L; Marciano C; Dellegrottaglie S; Iesu I; Perrone Filardi P Eur Heart J; 2020 Sep; 41(35):3346-3358. PubMed ID: 32077924 [TBL] [Abstract][Full Text] [Related]
17. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Pulipati VP; Ravi V; Pulipati P Eur J Prev Cardiol; 2020 Dec; 27(18):1922-1930. PubMed ID: 32089007 [TBL] [Abstract][Full Text] [Related]
18. Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials. Nreu B; Dicembrini I; Tinti F; Sesti G; Mannucci E; Monami M Nutr Metab Cardiovasc Dis; 2020 Jun; 30(7):1106-1114. PubMed ID: 32448716 [TBL] [Abstract][Full Text] [Related]
19. Cardiovascular Safety of Glucagon-Like Receptor 1 Agonists in Patients With Type 2 Diabetes and Peripheral Arterial Disease: A Meta-Analysis of Randomized Controlled Trials. Ashraf MT; Ali A; Ahmed N; Shakeel Khan MK; Usman M Am J Ther; 2024 Jul-Aug 01; 31(4):e483-e486. PubMed ID: 38976535 [No Abstract] [Full Text] [Related]
20. [The combination of GLP-1 analogs and SGLT2 inhibitors : new perspectives ?]. Ritz C; Jaafar J; Philippe J Rev Med Suisse; 2017 May; 13(565):1134-1139. PubMed ID: 28639755 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]